“
“Prevention of cardiovascular disease, undoubtedly an emphasis of clinical care in 2014, will provide both opportunities and challenges to patients and their healthcare providers. The recently-released ACC/AHA guidelines on assessment of cardiovascular risk, lifestyle management to reduce cardiovascular risk, management of overweight and obesity, and treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk, have introduced new concepts and revised prior conventional strategies. New to risk assessment are the Pooled Cohort Equations, targeting the expanded concept of atherosclerotic
cardiovascular disease (ASCVD) and focusing not solely on mortality but as well on major nonfatal events. The lifestyle management Selleck SB273005 focuses on diet and physical activity for lipid and blood pressure control. The cholesterol guideline identifies four high-risk groups with the greatest benefits from statin therapy: preexisting ASCVD, primary LDL-C elevations 190mm/dl, those 45-75 years with diabetes and LDL-C 70-189 mm/dl without clinical ASCVD, and those 40-75 years without clinical ASCVD with an LDL-C 70-189 mg/dl with a 7.5% or greater 10-year ASCVD risk. Eliminated are arbitrary LDL-C treatment targets, with
individual patient risk status guiding who should take statins GS-7977 clinical trial and the appropriate intensity of statin drugs. Patient-physician discussions of individual benefits and risks are paramount. Management of high blood pressure remains controversial, with two different expert panels offering varying treatment targets; there is general agreement on a <140/90 mmHg goal, but substantial disagreement on blood pressure targets for older adults. Clinicians and their patients deserve a well-researched concensus document.”
“Although it has been SRT1720 known for decades
that the drug nicotine can improve cognitive function, the nature of its effects and the underlying mechanisms are not well understood. Nicotine activates nicotinic acetylcholine (ACh) receptors (nAChRs) that normally are activated by endogenous ACh, presumably “”hijacking”" the cholinergic contribution to multiple cognitive functions, notably attention. Thus, studying nicotine’s effects helps to better understand a commonly used drug as well as functions of nAChRs. Moreover, nicotinic agonists are being developed to treat a variety of disorders that involve attention-related or age-related cognitive dysfunction. Studies have shown that nicotine can enhance processing of attended stimuli and/or reduce processing of distracters; that is, nicotine enhances attentional filtering.